Hilal T. Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management. Therapeutic Advances in Medical Oncology. 2017;9(3):189-199. doi:10.1177/1758834016678149.
Derks JL, van Suylen RJ, Thunnissen E, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? The European Respiratory Journal. 2017;49(6):1601838. doi:10.1183/13993003.01838-2016.
Horn L, Eisenberg R, Guis D et al. Chapter 72: Cancer of the Lung – Non-small Cell Lung Cancer and Small Cell Lung. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa. Elsevier: 2014.
Melosky B. Low Grade Neuroendocrine Tumors of the Lung. Frontiers in Oncology. 2017;7:119. doi:10.3389/fonc.2017.00119.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. V.2.2018. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf on July 11, 2018.
Pelosi G, Sonzogni A, Harari S, et al. Classification of pulmonary neuroendocrine tumors: new insights. Translational Lung Cancer Research. 2017;6(5):513-529. doi:10.21037/tlcr.2017.09.04.